Advertisement
Advertisement


Medical News

FDA Fast-Tracks Salix's Diarrhea Drug Review

February 13, 2012

The US Food and Drug Administration has granted priority review designation to crofelemer, an experimental treatment for HIV-associated diarrhea, the manufacturer Salix Pharmaceuticals Ltd. reported. Priority review status means the agency aims to complete its analysis of the application within six months, rather than the customary 10 months; FDA has set an action date of June 5 for the application. Salix -- based in Raleigh, N.C. -- holds North American and European rights to the drug; it has a supply agreement with India's Glenmark Pharmaceuticals Ltd.

Back to other news for February 2012

Adapted from:
Reuters
02.07.2012




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.